<DOC>
	<DOC>NCT02074995</DOC>
	<brief_summary>Study of tolerability and efficacy of BVS857 in severe burn subjects over 8 weeks and 15 weeks</brief_summary>
	<brief_title>Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects</brief_title>
	<detailed_description>No formal analysis was performed as study was terminated due to low enrollment issues. (n=1 patient was enrolled)</detailed_description>
	<mesh_term>Burns</mesh_term>
	<criteria>Burn injury comprising 2nd degree deep partial thickness and/or 3rd degree full thickness burns, â‰¥20% total body surface area with expected need for surgical intervention and not exceeding the sum of age plus burn size of 100 (Baux score) Dosing must occur within 812 days postburn Subjects must weigh at least 45kgs (for group 1 with doses of 0.03mg/kg) and be under 100 kg to participate in the study Spinal cord injury Hypoxic brain injury (Glasgow Coma Scale (GCS) &lt;8) at screening True conductive electric burn with suspected neurologic injury Uncontrolled diabetes with HbA1c &gt; 10% at screening, or known history of hypoglycemia, History of or active peripheral neuropathy or seizure disorder Systemic corticosteroids : &gt; 10mg/d of prednisone or equivalent, other investigational treatments (excluding investigational dressings), medications for weight loss including megestrol acetate, androgens or oral beta agonists</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Burn, Severe burn, Lean body mass, Cachexia, Hypermetabolism, Catabolism, Wound healing</keyword>
</DOC>